SCHEMBL419084

SCHEMBL419084

COC(=O)c1cc(Cl)ccc1NC(=O)/C=C/c1cccc(C2=CCCCC2)c1

nearest known ligand 0.55

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
SERPINE1 P05121 1/20 0.55
ALDH1A1 P00352 7/20 0.45
HPGD P15428 7/20 0.45
KDM4E B2RXH2 4/20 0.45
SMN1; SMN2 Q16637 3/20 0.45
RAB9A P51151 2/20 0.45
MEN1 O00255 1/20 0.45
NPC1 O15118 1/20 0.45
CYP1A2 P05177 1/20 0.45
CYP3A4 P08684 1/20 0.45
CYP2C19 P33261 1/20 0.45
KMT2A Q03164 1/20 0.45
EGFR P00533 1/20 0.43
MMP1 P03956 5/20 0.43
MMP2 P08253 5/20 0.43
MMP9 P14780 5/20 0.43
MAPT P10636 1/20 0.42
MAOB P27338 1/20 0.42
NPSR1 Q6W5P4 2/20 0.42
HTT P42858 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL419085 1.00 SERPINE1 (0.55) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL420395 0.90 SERPINE1 (0.68) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL420396 0.90 SERPINE1 (0.68) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL420830 0.83 EGFR (0.57) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL420831 0.83 EGFR (0.57) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL417564 0.82 SERPINE1 (0.80) SERPINE1ALDH1A1HPGDKDM4ESMN1; SMN2
SCHEMBL417436 0.79 ALDH1A1 (0.47) ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A
SCHEMBL417435 0.79 ALDH1A1 (0.47) ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A
SCHEMBL418392 0.78 MAOB (0.53) ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A
SCHEMBL418393 0.78 MAOB (0.53) ALDH1A1HPGDKDM4ESMN1; SMN2RAB9A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 6 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2607348-B1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE INC (JP) 2021-03-17 EP disclosed
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR RENASCIENCE CO LTD (JP) 2014-10-02 US disclosed
US-8785473-B2 Plasminogen activator inhibitor-1 inhibitor RENASCIENCE CO., LTD. (JP) 2014-07-22 US disclosed
EP-2607348-A2 Plasminogen Activator Inhibitor-1 Inhibitor Renascience CO., LTD. (JP) 2013-06-26 EP disclosed
EP-2415755-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR Renascience CO., LTD. (JP) 2012-02-08 EP disclosed
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor RENASCIENCE CO., LTD. (JP) 2012-01-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140296256-A1 PLASMINOGEN ACTIVATOR INHIBITOR-1 INHIBITOR SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885ALDH1A1 1450/4885HPGD 904/4885
US-20120022080-A1 Plasminogen Activator Inhibitor-1 Inhibitor SERPINE1, SERPINC1, SERPINB1 SERPINE1 1/4885ALDH1A1 1450/4885HPGD 904/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.